Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-07-05T02:01:13.373Z Has data issue: false hasContentIssue false

1012 – Evaluation Of a Risk-scale For Anticholinergic Side-effects In Elderly Psychiatric Inpatients

Published online by Cambridge University Press:  15 April 2020

G. Hefner
Affiliation:
Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany
A. Fellgiebel
Affiliation:
Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany
C. Hiemke
Affiliation:
Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Many commonly prescribed drugs have anticholinergic properties which can induce side-effects e.g. delirium, especially in an ageing brain with increased sensitivity. Risk-assessment before starting therapy may prevent such sideeffects.

Objectives

We rated anticholinergic pharmacological properties of prescribed medication and compared the theoretical risk with side-effects in clinical practice.

Aims

The scale should improve the safety of pharmacotherapy in gerontopsychiatry.

Methods

Based on five publications that considered anticholinergic properties of drugs, a risk-scale was established. Riskpoints for all drugs were summarized to a total score. Patients were selected from TDM-requests and data on patients’ sideeffects obtained from medical files. Reported anticholinergic side-effects including delirium were assessed retrospectively by the UKU-rating scale. Using linear regression and Spearman's correlation-analysis a possible correlation between risk-score points and severity of side-effects was determined.

Results

The screened sample consisted of 53 patients. 38 patients aged from 64 to 89 years (mean 74±6, 63.2% women) could be included for analysis. They had 93 plasma-level determinations (mean 2.4 requests per patient). According to their medication, patients attained by mean 4.51±2.98 risk-points (range 0-16). Mean UKU severity-index of side-effects was 0.81 (±0.99). Risk-points correlated significantly with observed anticholinergic side-effects and delirium (R2=.631, P< 0.001, CI 95%). Spearman correlation-coefficient was 0.731 (P< 0.01, CI 95%).

Conclusions

Since the established risk-scale correlated well with reported anticholinergic side-effects we recommend to implement this in the planning of psychopharmacological treatment to improve the safety of pharmacotherapy in gerontopsychiatry. For practical reasons it should be amalgamated with therapeutic drug monitoring as Geronto-TDM.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.